Allergan's most recent trend suggests a bearish bias. One trading opportunity on Allergan is a Bear Call Spread using a strike $130.00 short call and a strike $135.00 long call offers a potential 46.63% return on risk over the next 14 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $130.00 by expiration. The full premium credit of $1.59 would be kept by the premium seller. The risk of $3.41 would be incurred if the stock rose above the $135.00 long call strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Allergan is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Allergan is bearish.
The RSI indicator is at 34.36 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Allergan
Ironwood Initiates Dosing in Mid-Stage Study for MD-7246
Wed, 05 Jun 2019 13:50:01 +0000
Ironwood (IRWD)and its partner initiate dosing in a phase II study evaluating delayed-release version of Linzess, MD-7246, in patients with IBS-D.
Watch These 9 Companies in a Botox Export Boom Out of South Korea
Mon, 03 Jun 2019 18:00:00 +0000
South Korea is the capital of K-pop – and plastic surgery. One in three women between the ages of 19 and 29 have had a vanity operation, according to Gallup Korea, although some Koreans say the figure is higher. There is a clutch of nine companies that have started manufacturing or selling botox in Korea.
Johnson & Johnson Stock Falls as Its Opioid Trial Gets Underway
Wed, 29 May 2019 20:15:00 +0000
Johnson & Johnson, like other makers of opioid drugs, is the target of a number of lawsuits for its alleged role in the opioid crisis. The first major trial began this week in Oklahoma.
Allergan's (AGN) Vraylar Gets FDA Nod for Bipolar Depression
Wed, 29 May 2019 14:34:02 +0000
Allergan's (AGN) sNDA for Vraylar gets the FDA approval for the treatment of adult patients with major depressive episodes related to bipolar I disorder.
Allergan to recall textured breast implants in Canada
Tue, 28 May 2019 20:58:09 +0000
Allergan Plc said on Tuesday it will voluntarily recall and stop the sale of its Biocell textured breast implants in Canada after the country's health agency suspended the company's licenses for the implants, citing increased risk of cancer. The Botox-maker in December took its textured breast implants off the market in Europe after a French regulatory body ordered a recall. The potential risks associated with the implants outweigh their benefits, including the rare but serious risk of BIA-ALCL, Health Canada said http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20190528:nCNWzfkNpa on Tuesday.
Also on Market Tamer…
Follow Us on Facebook